Evidence map›Paper›PMID 38338848›Full record

ArticleInternational journal of molecular sciences2024

Establishing Monoclonal Gammopathy of Undetermined Significance as an Independent Pre-Disease State of Multiple Myeloma Using Raman Spectroscopy, Dynamical Network Biomarker Theory, and Energy Landscape Analysis.

Shota Yonezawa, Takayuki Haruki, Keiichi Koizumi, Akinori Taketani, Yusuke Oshima, Makito Oku, Akinori Wada, Tsutomu Sato, Naoki Masuda, Jun Tahara and 5 more

Abstract read
In one paragraph

Article in International journal of molecular sciences, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed.

  1. Article
  2. Article
  3. Article
  4. Observational
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

15 authors.

Shota YonezawaResearch Center for Pre-Disease Science, University of Toyama, Toyama 930-8555, Japan.ORCID 0009-0009-3605-7379
Takayuki HarukiResearch Center for Pre-Disease Science, University of Toyama, Toyama 930-8555, Japan.ORCID 0000-0003-2718-0972
Keiichi KoizumiResearch Center for Pre-Disease Science, University of Toyama, Toyama 930-8555, Japan.ORCID 0000-0002-0349-4144
Akinori TaketaniResearch Center for Pre-Disease Science, University of Toyama, Toyama 930-8555, Japan.ORCID 0000-0003-4637-8167
Yusuke OshimaResearch Center for Pre-Disease Science, University of Toyama, Toyama 930-8555, Japan.ORCID 0000-0002-2304-8600
Makito OkuResearch Center for Pre-Disease Science, University of Toyama, Toyama 930-8555, Japan.ORCID 0000-0002-0282-2361
Akinori WadaResearch Center for Pre-Disease Science, University of Toyama, Toyama 930-8555, Japan.ORCID 0000-0002-6218-519X
Tsutomu SatoResearch Center for Pre-Disease Science, University of Toyama, Toyama 930-8555, Japan.ORCID 0000-0003-2712-2713
Naoki MasudaDepartment of Mathematics, State University of New York at Buffalo, Buffalo, NY 14260-2900, USA.ORCID 0000-0003-1567-801X
Jun TaharaDivision of Presymptomatic Disease, Institute of Natural Medicine, University of Toyama, Toyama 930-0194, Japan.
Noritaka FujisawaGraduate School of Science and Engineering, University of Toyama, Toyama 930-8555, Japan.
Shota KoshiyamaDivision of Presymptomatic Disease, Institute of Natural Medicine, University of Toyama, Toyama 930-0194, Japan.
Makoto KadowakiResearch Center for Pre-Disease Science, University of Toyama, Toyama 930-8555, Japan.ORCID 0000-0002-5945-9380
Isao KitajimaResearch Center for Pre-Disease Science, University of Toyama, Toyama 930-8555, Japan.ORCID 0000-0001-6156-4481
Shigeru SaitoResearch Center for Pre-Disease Science, University of Toyama, Toyama 930-8555, Japan.ORCID 0000-0002-8940-3708

Funding

Japan Science and Technology Agency JPMJMS2021
6 · The paper itself

Abstract

Multiple myeloma (MM) is a cancer of plasma cells. Normal (NL) cells are considered to pass through a precancerous state, such as monoclonal gammopathy of undetermined significance (MGUS), before transitioning to MM. In the present study, we acquired Raman spectra at three stages-834 NL, 711 MGUS, and 970 MM spectra-and applied the dynamical network biomarker (DNB) theory to these spectra. The DNB analysis identified MGUS as the unstable pre-disease state of MM and extracted Raman shifts at 1149 and 1527-1530 cm-1 as DNB variables. The distribution of DNB scores for each patient showed a significant difference between the mean values for MGUS and MM patients. Furthermore, an energy landscape (EL) analysis showed that the NL and MM stages were likely to become stable states. Raman spectroscopy, the DNB theory, and, complementarily, the EL analysis will be applicable to the identification of the pre-disease state in clinical samples.

Indexed as

Monoclonal Gammopathy of Undetermined SignificanceMultiple MyelomaParaproteinemiasBiomarkersDisease ProgressionHumansSpectrum Analysis, RamanBiomarkersdynamical network biomarker theoryenergy landscape analysismonoclonal gammopathy of undetermined significancemultiple myelomaRaman spectroscopy

Identifiers

PMID38338848
PMCPMC10855579

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.